Additive Relationship Between Serum Fibroblast Growth Factor 21 Level and Coronary Artery Disease

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2013 Aug 29

PMID 23981342

Citations 73

Authors

Yun Shen

Xiaojing Ma

Jian Zhou

Xiaoping Pan

Yaping Hao

Mi Zhou

Zhigang Lu

Meifang Gao

Yuqian Bao

Weiping Jia

Affiliations

Soon will be listed here.

Abstract

Background: Expression and activity of the fibroblast growth factor (FGF) 21 hormone-like protein are associated with development of several metabolic disorders. This study was designed to investigate whether serum FGF21 level was also associated with the metabolic syndrome-related cardiovascular disease, atherosclerosis, and its clinical features in a Chinese cohort.

Methods: Two-hundred-and-fifty-three subjects visiting the Cardiology Department (Sixth People's Hospital affiliated to Shanghai JiaoTong University) were examined by coronary arteriography (to diagnose coronary artery disease (CAD)) and hepatic ultrasonography (to diagnose non-alcoholic fatty liver disease (NAFLD)). Serum FGF21 level was measured by enzyme-linked immunosorbent assay and analyzed for correlation to subject and clinical characteristics. The independent factors of CAD were determined by multivariate logistic regression analysis.

Results: Subjects with NAFLD showed significantly higher serum FGF21 than those without NAFLD (388.0 pg/mL (253.0-655.4) vs. 273.3 pg/mL (164.9-383.7), P < 0.01). Subjects with CAD showed significantly higher serum FGF21, regardless of NAFLD diagnosis (P < 0.05). Serum FGF21 level significantly elevated with the increasing number of metabolic disorders (P for trend < 0.01). After adjustment of age, sex, and BMI, FGF21 was positively correlated with total cholesterol (P < 0.05) and triglyceride (P < 0.01). FGF21 was identified as an independent factor of CAD (odds ratio = 2.984, 95% confidence interval: 1.014-8.786, P < 0.05).

Conclusions: Increased level of serum FGF21 is associated with NAFLD, metabolic disorders and CAD.

Citing Articles

Low Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto's Thyroiditis on Levothyroxine Substitution.

Berta E, Halmi S, Molnar I, Hutkai D, Csiha S, Bhattoa H Metabolites. 2024; 14(10).

PMID: 39452947 PMC: 11509456. DOI: 10.3390/metabo14100565.

The Correlation Between Serum Fibroblast Growth Factor 21 and the Severity and Occurrence of Coronary Artery Disease.

Sinha S, Prakash P, Keshari J, Prasad R Cureus. 2024; 16(1):e51924.

PMID: 38333506 PMC: 10851179. DOI: 10.7759/cureus.51924.

Biomarkers of Hepatic Dysfunction and Cardiovascular Risk.

Lee Jr T, Kueh M, Jain V, Razavi A, Alebna P, Chew N Curr Cardiol Rep. 2023; 25(12):1783-1795.

PMID: 37971635 PMC: 10902719. DOI: 10.1007/s11886-023-01993-5.

The association of serum Klotho concentrations with hyperlipidemia prevalence and lipid levels among US adults: a cross-sectional study.

Jiang S, Wang Y, Wang Z, Zhang L, Jin F, Li B BMC Public Health. 2023; 23(1):1645.

PMID: 37641103 PMC: 10463308. DOI: 10.1186/s12889-023-16566-y.

Fibroblast growth factor 21 in metabolic syndrome.

Yang M, Liu C, Jiang N, Liu Y, Luo S, Li C Front Endocrinol (Lausanne). 2023; 14:1220426.

PMID: 37576954 PMC: 10414186. DOI: 10.3389/fendo.2023.1220426.

References

Gorar S, Culha C, Uc Z, Dellal F, Serter R, Aral S . Serum fibroblast growth factor 21 levels in polycystic ovary syndrome. Gynecol Endocrinol. 2010; 26(11):819-26. DOI: 10.3109/09513590.2010.487587. View

Jian-gao F . Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi. 2010; 18(3):163-6. View

Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D . Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009; 71(3):369-75. DOI: 10.1111/j.1365-2265.2008.03502.x. View

Lee Y, Lim S, Hong E, Kim J, Moon M, Chun E . Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clin Endocrinol (Oxf). 2013; 80(1):57-64. DOI: 10.1111/cen.12134. View

Cheng X, Zhu B, Jiang F, Fan H . Serum FGF-21 levels in type 2 diabetic patients. Endocr Res. 2011; 36(4):142-8. DOI: 10.3109/07435800.2011.558550. View

Monsour Jr H, Frenette C, Wyne K . Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J. 2012; 8(3):21-5. PMC: 3487573. DOI: 10.14797/mdcj-8-3-21. View

An S, Lee M, Yi S, Ha E, Han S, Kim H . Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract. 2012; 96(2):196-203. DOI: 10.1016/j.diabres.2012.01.004. View

Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X . Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010; 53(5):934-40. DOI: 10.1016/j.jhep.2010.05.018. View

Stein S, Stepan H, Kratzsch J, Verlohren M, Verlohren H, Drynda K . Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia. Metabolism. 2009; 59(1):33-7. DOI: 10.1016/j.metabol.2009.07.003. View

10.

Reinehr T, Woelfle J, Wunsch R, Roth C . Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab. 2012; 97(6):2143-50. DOI: 10.1210/jc.2012-1221. View

11.

Dostalova I, Haluzikova D, Haluzik M . Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physiol Res. 2009; 58(1):1-7. DOI: 10.33549/physiolres.931610. View

12.

Semba R, Sun K, Egan J, Crasto C, Carlson O, Ferrucci L . Relationship of serum fibroblast growth factor 21 with abnormal glucose metabolism and insulin resistance: the Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2012; 97(4):1375-82. PMC: 3319186. DOI: 10.1210/jc.2011-2823. View

13.

Li H, Dong K, Fang Q, Hou X, Zhou M, Bao Y . High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China. J Hepatol. 2012; 58(3):557-63. DOI: 10.1016/j.jhep.2012.10.029. View

14.

Tyynismaa H, Raivio T, Hakkarainen A, Ortega-Alonso A, Lundbom N, Kaprio J . Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab. 2010; 96(2):E351-5. DOI: 10.1210/jc.2010-1326. View

15.

Li H, Bao Y, Xu A, Pan X, Lu J, Wu H . Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab. 2009; 94(6):2151-6. DOI: 10.1210/jc.2008-2331. View

16.

Lu Y, Liu J, Zhang L, Du J, Zeng X, Hao G . Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells. Chin Med J (Engl). 2011; 123(23):3417-21. View

17.

Kawamoto R, Kohara K, Kusunoki T, Tabara Y, Abe M, Miki T . Alanine aminotransferase/aspartate aminotransferase ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults. Cardiovasc Diabetol. 2012; 11:117. PMC: 3499385. DOI: 10.1186/1475-2840-11-117. View

18.

JUDKINS M . Percutaneous transfemoral selective coronary arteriography. Radiol Clin North Am. 1968; 6(3):467-92. View

19.

Yang G, Fan L, Tan J, Qi G, Zhang Y, Samet J . Smoking in China: findings of the 1996 National Prevalence Survey. JAMA. 1999; 282(13):1247-53. DOI: 10.1001/jama.282.13.1247. View

20.

Coskun T, Bina H, Schneider M, Dunbar J, Hu C, Chen Y . Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008; 149(12):6018-27. DOI: 10.1210/en.2008-0816. View